BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Sangamo Therapeutics, Inc. SGMOQ
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$39.6M
▼ 31.6% vs FY2024
EPS · FY25
$-0.44
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-2891.8%
Net margin · FY25
-310.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 39.6M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 311 cents on every revenue dollar this year.
Per share
USD -0.44
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-2891.8%
Return on equity, FY2025
ROE
Operating margin-306.5%
Net margin-310.8%
Return on assets-152.4%
Each USD of equity lost 2892 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−19.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−29.2%
−19.7%
+0.0%
+4.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.35B
Shares outstanding, FY2025
Change, 5 years+83.5%
Change, 10 years+208.2%
The share count grew 84% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 59.7M
total assets, end of FY2025
Total assetsUSD 59.7M
EquityUSD -14.3M
CashUSD 20.9M
Current ratio0.84×
Equity funds -24% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
·
·
·
·
·
Net income $B
−0.1
−0.1
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.44
−0.49
−1.48
−1.25
−1.23
−0.90
−0.85
−0.70
−0.70
−1.02
−0.58
−0.39
−0.48
−0.42
−0.71
−0.55
−0.44
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−2891.8
−185.4
−136.5
−57.4
−40.8
−26.0
−23.8
−24.7
−33.7
−43.6
−20.4
−16.1
−28.5
−30.7
−52.6
−38.9
−25.9
Shares out B
0.35
0.21
0.18
0.17
0.15
0.14
0.12
0.10
0.09
0.07
0.07
0.07
0.06
0.05
0.05
0.05
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed